GLP1_NEW
Visepegenatide injection
VISEPE_SC
Doses in this pooled treatment
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.56 (-1.08 to -0.04) | 0.28 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.57 (-1.18 to 0.12) | 0.32 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.51 (-3.34 to 2.48) | 0.36 |
| Type 2 diabetes (adults) | HbA1c change | weeks 20 to 36 (target week 26) | Placebo | MD -0.74 (-1.34 to -0.08) | 0.40 |
| Type 2 diabetes (adults) | Body weight change in kilograms (diabetes) | weeks 20 to 36 (target week 26) | Placebo | MD 0.11 (-1.97 to 2.19) | 0.50 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 3.03 (1.38 to 6.42) | 0.40 |
| Type 2 diabetes (adults) | HbA1c below 7 percent | weeks 20 to 36 (target week 26) | Placebo | OR 5.32 (0.85 to 25.69) | 0.38 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.28 (0.00 to 14.14) | 0.49 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 1.39 (0.51 to 3.96) | 0.54 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.49 (0.01 to 33.98) | 0.61 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 1.29 (0.63 to 2.71) | 0.34 |
| Type 2 diabetes (adults) | Discontinuation due to adverse events | longest follow-up | Placebo | HR 2.47 (0.36 to 23.92) | 0.34 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 9.97 (2.99 to 45.99) | 0.08 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 14.88 (3.72 to 92.58) | 0.08 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 2.13 (1.09 to 4.19) | 0.31 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.74 (0.04 to 10.40) | 0.43 |
Trials
- PB119A Phase III, Multicenter, Randomized, Double-blind, Parallel, Placebo-controlled Trial to Evaluate the Efficacy and Safety of Pegylated Exenatine Injection (PB-119) in Drug-naïve T2DM Subjects2020 · 273 randomized · 24 weeks
- NCT04504396A Multicenter, Randomized, Double-blinded, Placebo-controlled Trial Comparing the Efficacy and Safety of PB-119 in Combination With Metformin in Subjects With Type 2 Diabetes Mellitus Inadequately Controlled on Metformin Alone2020 · 620 randomized · 24 weeks